Kinoxis Therapeutics Pty Ltd
Kinoxis Therapeutics is a pre-clinical stage, private biotechnology company based in Australia that is developing of a range of novel therapeutic compounds for the treatment of substance use disorders and other CNS conditions. The company’s lead candidate, KNX100, is being developed for the treatment of opioid withdrawal and is undergoing pre-clinical testing, with the accompany on track to commence a Phase 1 human trial in late 2020.
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.